Opinion|Videos|August 5, 2024
Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities
Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.
Advertisement
Episodes in this series
- Briefly comment on recent real world data regarding switching and sequencing to next line of therapy in patients with CLL. (
Pinilla-Ibarz, et al. EHA 2024. Abstract P697 ) - How do you interpret these data and how may they influence your overall treatment approach?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
4
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
5